Temozolomide and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
- Sponsor
- Swiss Cancer Institute
- Study ID
- NCT00568048
- Phase
- PHASE2
- Status
- Completed
Conditions
- Melanoma (Skin)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- bevacizumab — BIOLOGICAL10 mg/kg i.v., on day 1 of every cycle (14 days) until PD or any other event qualifying for stopping treatment
- temozolomide — DRUG150 mg/m2 p.o., on days 1-7 of every cycle (14 days) until PD or any other event qualifying for stopping treatment
Study Details
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving temozolomide together with bevacizumab may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving temozolomide together with bevacizumab works in treating patients with stage IV melanoma that cannot be removed by surgery.
Key Dates
- First listed
- Dec 5, 2007
- Start date
- Dec 31, 2007
- Status verified
- Apr 2013
- Primary completion
- Dec 31, 2010
- Completion
- Oct 31, 2011
Study Design
- Enrollment
- 62 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Combination Therapy Temozolomide & BevacizumabCombination therapy * Temozolomide 150 mg/m2 p.o., days 1-7, repeated every 14 days * Bevacizumab 10 mg/kg i.v., day 1, repeated every 14 days
Primary Outcome Measure
Clinical benefit number of patients with complete response [CR], partial response [PR], or stable disease) according to RECIST criteria [ Time Frame: at 12 weeks ]
Related Studies
- Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain MetastasesPHASE2 · Recruiting · M.D. Anderson Cancer Center · Houston, Texas
- High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO TrialRecruiting · Fred Hutchinson Cancer Center · Boston, Massachusetts
- Identification of Metabolic Phenotypes Associated With Melanoma MetastasisRecruiting · University of Texas Southwestern Medical Center · Dallas, Texas
- Rural Adult and Youth Sun Protection StudyRecruiting · University of Utah · Salt Lake City, Utah